Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CG-BM1
- Development stage
- Phase 2
- Lead developer
- Guangzhou Saijun Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CG-BM1 is an allogeneic human bone marrow-derived mesenchymal stem cell (hBM-MSC) therapy developed by Guangzhou Cellgene Biotech. It is currently in clinical development for the treatment of acute-on-chronic liver failure (ACLF). The therapy utilizes the innate immunomodulatory and regenerative properties of mesenchymal stem cells to address the intense systemic inflammation and hepatic tissue damage characteristic of ACLF. When administered intravenously, these cells are thought to home to the liver and release a variety of paracrine factors, including anti-inflammatory cytokines and growth factors, which help to stabilize the immune response and promote the repair of damaged hepatocytes. The Phase 1 trial (NCT06386328) is designed to evaluate the safety, tolerability, and preliminary efficacy of CG-BM1 in this patient population.
- Other names
- Allogeneic Human Bone Marrow Mesenchymal Stem Cell InjectionhBM-MSCsAllogeneic Human Bone Marrow Mesenchymal Stem Cells
Beyond the preview
Go deeper on CG-BM1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CG-BM1.